 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.  
         Italics indicate opposite chamber/conference committee amendments.             *sb0357*      
SENATE BILL 357  
J1, J5    (5lr2092 ) 
ENROLLED BILL  
— Finance/Health and Government Operations  — 
Introduced by Senators Gile  and Feldman , Feldman, and Hester  
 
Read and  Examined by Proofreaders:  
 
_______________________________________________  
Proofreader.  
_______________________________________________  
Proofreader.  
 
Sealed with the Great Seal and presented to the Governor, for his approval this  
  
_______ day of ________ _______ at ________________________ o’clock, ________M.  
  
______________________________________________  
President .  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Prescription Drug Affordability Board – Authority for Upper Payment Limits  2 
and Stakeholder Council Membership  3 
(Lowering Prescription Drug Costs for All Marylanders Now Act)  4 
 
FOR the purpose of altering the membership of the Prescription Drug Affordability 5 
Stakeholder Council;  requiring the Prescription Drug Affordability Board, under 6 
certain circumstances, to establish a process for setting upper payment limits for all 7 
purchases and payor reimbursements of prescription drug products in the State that 8 
the Board determines have led or will lead to affordability challenges; authorizing 9 
the Board to reconsider an upper payment limit for a drug that becomes a current 10 
shortage; altering requirements related to the setting of upper payment limits by the 11 
Board; requiring the Board to c onfer with the Maryland Medical Assistance Program 12 
before establishing an upper payment limit that applies to the Program;  prohibiting 13 
the Board from taking certain actions related to upper payment limits; and generally 14 
relating to the Prescription Drug Af fordability Board.  15 
2 SENATE BILL 357   
 
  
BY repealing and reenacting, with amendments,  1 
 Article – Health – General  2 
Section 21 –2C–01, 21–2C–04, 21–2C–13, and 21 –2C–14 3 
 Annotated Code of Maryland  4 
 (2023 Replacement Volume and 2024 Supplement)  5 
 
BY repealing and reenacting, wit hout amendments,  6 
 Article – Health – General  7 
Section 21–2C–09(c) and  21–2C–11(a)  8 
 Annotated Code of Maryland  9 
 (2023 Replacement Volume and 2024 Supplement)  10 
 
BY adding to  11 
 Article – Health – General  12 
 Section 21 –2C–09(d) and (e) and 21 –2C–16 13 
 Annotated Code of Maryland  14 
 (2023 Replacement Volume and 2024 Supplement)  15 
 
BY repealing  16 
 Article – Health – General  17 
Section 21 –2C–11(d) and 21 –2C–16 18 
 Annotated Code of Maryland  19 
 (2023 Replacement Volume and 2024 Supplement)  20 
 
BY adding to  21 
 Article – Health – General  22 
Section 21 –2C–16 23 
 Annotated Code of Maryland  24 
 (2023 Replacement Volume and 2024 Supplement)  25 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 26 
That the Laws of Maryland read as follows:  27 
 
Article – Health – General  28 
 
21–2C–01. 29 
 
 (a) In this subtitle  the following words have the meanings indicated.  30 
 
 (b) “Biologic” means a drug that is produced or distributed in accordance with a 31 
biologics license application approved under 42 C.F.R. § 447.502.  32 
 
 (c) “Biosimilar” means a drug that is produced or distributed in accordance with 33 
a biologics license application approved under 42 U.S.C. § 262(k)(3).  34 
 
 (d) “Board” means the Prescription Drug Affordability Board.  35 
 SENATE BILL 357  3 
 
  
 (e) (1) “Brand name drug” means a drug that is produced or distributed in 1 
accordance with an original new drug application approved under 21 U.S.C. § 355(c).  2 
 
  (2) “Brand name drug” does not include an authorized generic as defined 3 
by 42 C.F.R. § 447.502.  4 
 
 (F) “CURRENT SHORTAGE ” MEANS A DRUG : 5 
 
  (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG 6 
ADMINISTRATION ’S DRUG SHORTAGE DATABASE ; OR 7 
 
  (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT 8 
SUPPLY IN THE STATE . 9 
 
 [(f)] (G) “Generic drug” means:  10 
 
  (1) A retail drug that is marketed or distributed in accordance with an 11 
abbreviated new drug a pplication, approved under 21 U.S.C. § 355(j);  12 
 
  (2) An authorized generic as defined by 42 C.F.R. § 447.502; or  13 
 
  (3) A drug that entered the market before 1962 that was not originally 14 
marketed under a new drug application.  15 
 
 [(g)] (H) “Manufacturer” means an entity that:  16 
 
  (1) (i) Engages in the manufacture of a prescription drug product; or  17 
 
   (ii) Enters into a lease with another manufacturer to market and 18 
distribute a prescription drug product under the entity’s own name; and  19 
 
  (2) Sets or chang es the wholesale acquisition cost of the prescription drug 20 
product it manufactures or markets.  21 
 
 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug, 22 
a biologic, or a biosimilar.  23 
 
 [(i)] (J) “Stakeholder Council” means the Prescription Drug Affordability 24 
Stakeholder Council.  25 
 
21–2C–04. 26 
 
 (a) There is a Prescription Drug Affordability Stakeholder Council.  27 
 
4 SENATE BILL 357   
 
  (b) The purpose of the Stakeholder Council is to provide stakeholder input to 1 
assist the Board in making decisions as re quired under this subtitle.  2 
 
 (c) (1) The Stakeholder Council consists of [26] members appointed in 3 
accordance with this subsection.  4 
 
  (2) The Speaker of the House of Delegates shall appoint:  5 
 
   (i) One representative of generic drug corporations;  6 
 
   (ii) One representative of nonprofit insurance carriers;  7 
 
   (iii) One representative of a statewide health care advocacy coalition;  8 
 
   (iv) One representative of a statewide advocacy organization for 9 
seniors;  10 
 
   (v) One representative of a statewide organization for diverse 11 
communities;  12 
 
   (vi) One representative of a labor union;  13 
 
   (vii) ONE REPRESENTATIVE OF  THE RARE DISEASE COM MUNITY ; 14 
 
   (VIII) One health services researcher specializing in prescription 15 
drugs; and  16 
 
   [(viii)] (IX) One public member at the discretion of the Speaker of the 17 
House of Delegates.  18 
 
  (3) The President of the Senate shall appoint:  19 
 
   (i) One representative of brand name drug corporations;  20 
 
   (ii) One representative of physicians;  21 
 
   (iii) One representative of nurs es; 22 
 
   (iv) One representative of hospitals;  23 
 
   (v) One representative of dentists;  24 
 
   (vi) ONE REPRESENTATIVE OF  ONCOLOGISTS ; 25 
 
   (VII) One representative of managed care organizations;  26 
 
 SENATE BILL 357  5 
 
    [(vii)] (VIII) One representative of the Department of Budget and 1 
Management;  2 
 
   [(viii)] (IX) One clinical researcher; and  3 
 
   [(ix)] (X) One public member at the discretion of the President of 4 
the Senate.  5 
 
  (4) The Governor shall appoint:  6 
 
   (i) One representative of brand name drug corporations;  7 
 
   (ii) One re presentative of generic drug corporations;  8 
 
   (iii) One representative of biotechnology companies;  9 
 
   (iv) One representative of for –profit health insurance carriers;  10 
 
   (v) One representative of employers;  11 
 
   (vi) One representative of pharmacy benefi ts managers;  12 
 
   (vii) One representative of pharmacists;  13 
 
   (viii)  One pharmacologist; [and] 14 
 
   (ix) ONE REPRESENTATIVE OF  A PATIENT ADVOCACY 15 
ORGANIZATION ; AND  16 
 
   (X) One public member at the discretion of the Governor.  17 
 
  (5) Collectively, the members  of the Stakeholder Council shall have 18 
knowledge of the following:  19 
 
   (i) The pharmaceutical business model;  20 
 
   (ii) Supply chain business models;  21 
 
   (iii) The practice of medicine or clinical training;  22 
 
   (iv) Consumer or patient perspectives;  23 
 
   (v) Health care costs trends and drivers;  24 
 
   (vi) Clinical and health services research; or  25 
 
6 SENATE BILL 357   
 
    (vii) The State’s health care marketplace.  1 
 
  (6) To the extent practicable and consistent with federal and State law, the 2 
membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity 3 
of the State.  4 
 
  (7) From among the membership of the Stakeholder Council, the Board 5 
chair shall appoint two members to be cochairs of the Stakeholder Council.  6 
 
 (d) (1) The term of a member is 3 years . 7 
 
  (2) The initial members of the Stakeholder Council shall serve staggered 8 
terms as required by the terms provided for members on October 1, 2019.  9 
 
 (e) A member of the Stakeholder Council:  10 
 
  (1) May not receive compensation as a member of the Stakeholder Council; 11 
but 12 
 
  (2) Is entitled to reimbursement for expenses under the Standard State 13 
Travel Regulations, as provided in the State budget.  14 
 
21–2C–09.  15 
 
 (c) On or before December 31, 2020, and each December 31 thereafter, the Board 16 
shall submi t to the Senate Finance Committee and the House Health and Government 17 
Operations Committee, in accordance with § 2 –1257 of the State Government Article, a 18 
report that includes:  19 
 
  (1) Price trends for prescription drug products;  20 
 
  (2) The number of prescr iption drug products that were subject to Board 21 
review and the results of the review; and  22 
 
  (3) Any recommendations the Board may have on further legislation 23 
needed to make prescription drug products more affordable in the State.  24 
 
 (D) IF THE BOARD SETS A  NEW UPPER PAYMENT LI MIT, TO THE EXTENT 25 
PRACTICABLE , THE BOARD SHALL INCLUDE I N THE FIRST REPORT T HAT IS 26 
REQUIRED UNDER SUBSE CTION (C) OF THIS SECTION AFTE R THE UPPER PAYMENT 27 
LIMIT HAS BEEN IN EF FECT FOR 1 YEAR INFORMATION ON THE EFFECTS OF THE 28 
UPPER PAYME NT LIMIT , BASED ON AVAILABLE T IMELY DATA , FOR THE FOLLOWING : 29 
 
  (1) PATIENT OUT –OF–POCKET COSTS INCLUDI NG WHETHER THE 30 
UPPER PAYMENT LIMIT WAS ASSOCIATED WITH INCREASES OR DECREAS ES IN WHAT 31 
PATIENTS PAY FOR PRE SCRIPTION DRUG PRODU CTS; 32 
 SENATE BILL 357  7 
 
  
  (2) PATIENT HEALTH INSURANCE PREMIUMS , INCLUDING WHETHER 1 
THE UPPER PAYMENT LI MIT IS ASSOCIATED WI TH INCREASES OR DECR EASES IN 2 
HEALTH INSURANCE COS TS FOR PATIENTS ; 3 
 
  (3) PHARMACIES OPERATING IN THE STATE , INCLUDING THE IMPACT  4 
ON REIMBURSEMENT RAT ES AND FINANCIAL VIA BILITY OF  RETAIL AND 5 
INDEPENDENT PHARMACI ES; 6 
 
  (4) PATIENT HEALTH INSURA NCE FORMULARIES , INCLUDING 7 
WHETHER THE PRESCRIP TION DRUG PRODUCT SU BJECT TO THE UPPER P AYMENT 8 
LIMIT REMAINED ON FO RMULARIES ; 9 
 
  (5) PROVIDER –ADMINISTERED MEDICAT IONS SUBJECT TO THE 10 
UPPER PAYMENT LIMIT , INCLUDING WHETHER PR OVIDERS WERE ABLE TO  ACQUIRE 11 
THE PRESCRIPTION DRU G PRODUCT SUBJECT TO  THE UPPER PAYMENT LI MIT AT A 12 
RATE TO ACCOUNT FOR ACQUISITION COSTS AN D WHETHER THERE WAS AN IMPACT 13 
ON PROVIDER REIMBURS EMENT ; 14 
 
  (6) PATIENT ACCESS TO THE PRESCRIPTION DRU G PRODUCT 15 
SUBJECT TO THE UPPER  PAYMENT LIMIT , WHICH MAY INCLUDE : 16 
 
   (I) WHETHER PRESCRIPTION DRUG PRODUCT SHORTAG ES OR 17 
OTHER SUPPLY DISRUPT IONS OCCURRED AFTER THE UPPER PAYMENT LI MIT TOOK 18 
EFFECT ; 19 
 
   (II) WHETHER FORMULARY PLA CEMENT OR  PLAN DESIGN 20 
CHANGES MADE THE PRE SCRIPTION DRUG PRODU CT SUBJECT TO THE UP PER LIMIT 21 
MORE DIFFICULT FOR P ATIENTS TO ACCESS , INCLUDING IF INSURAN CE PLANS 22 
PREFERRED A PRESCRIP TION DRUG PRODUCT WI THOUT AN UPPER PAYME NT LIMIT 23 
OVER A PRESCRIPTION DRUG PRODUCT SUB JECT TO AN UPPER PAY MENT LIMIT ; 24 
 
   (III) WHETHER THE DISTRIBUT ION AND DELIVERY OF 25 
SPECIALTY OR RARE DI SEASE MEDICATIONS FR OM OUT–OF–STATE PHARMACIES TO 26 
PROVIDERS , PHARMACIES , OR PATIENTS WAS IMPA CTED ; 27 
 
   (IV) WHETHER PATIENTS IN C OMMUNITIES OF COLOR , 28 
PAT IENTS WHO ARE WOMEN , PATIENTS WITH A RARE  DISEASE , OR PATIENTS IN 29 
RURAL AREAS EXPERIEN CED DISPROPORTIONATE  ACCESS CHALLENGES ; AND  30 
 
   (V) WHETHER COST DIFFEREN CES AS A RESULT OF T HE UPPER 31 
PAYMENT LIMIT AFFECT ED PATIENTS , PHARMACIES , OR PROVIDERS AND , IF THE 32 
COST DIFFERENCE RESU LTED IN AN INCREASE IN COSTS , WHO WAS ULTIMATELY 33 
RESPONSIBLE FOR BEAR ING THE INCREASED CO ST; 34 
8 SENATE BILL 357   
 
  
  (7) COVERED ENTITY PROVID ERS PARTICIPATING IN  THE 340B  DRUG 1 
DISCOUNT PROGRAM , INCLUDING THE IMPACT  OF THE UPPER PAYMENT  LIMIT ON 2 
THE OPE RATIONS OF THE PROVI DERS AND THEIR CONTR ACTED PHARMACIES ; AND  3 
 
  (8) THE BIOTECHNOLOGY IND USTRY IN THE STATE , INCLUDING THE 4 
IMPACT ON PHARMACEUT ICAL RESEARCH AND DE VELOPMENT , INVESTMENT , AND 5 
JOB GROWTH . 6 
 
 (E) (1) THE BOARD MAY REQUEST INF ORMATION NECESSARY  TO 7 
COMPLETE THE REPORT REQUIRED UNDER SUBSE CTIONS (C) AND (D) OF THIS 8 
SECTION FROM AN AFFE CTED ENTITY . 9 
 
  (2) THE ENTITY FROM WHICH  INFORMATION WAS REQU ESTED UNDER 10 
PARAGRAPH (1) OF THIS SUBSECTION S HALL MAKE A GOOD FAI TH EFFORT TO 11 
PROVIDE THE REQUESTE D IN FORMATION .  12 
 
21–2C–11. 13 
 
 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.  14 
 
 [(d) (1) The Board shall be established using special or general funds, which 15 
shall be repaid to the State with the funds from the Fund.  16 
 
  (2) If the Board receives funding from the Maryland Health Care 17 
Commission under paragraph (1) of this subsection, the Board shall repay the funds to the 18 
Commission from the Fund over a 3 –year period beginning June 1, 2021. ] 19 
 
21–2C–13. 20 
 
 (a) If, under § 21 –2C–07 of t his subtitle, the Board finds that it is in the best 21 
interest of the State to establish a process for setting upper payment limits for prescription 22 
drug products that it determines have led or will lead to an affordability challenge, the 23 
Board, in conjunct ion with the Stakeholder Council, shall draft a plan of action for 24 
implementing the process  [that includes the criteria the Board shall use to set upper 25 
payment limits ] IN ACCORDANCE WITH T HE REQUIREMENTS OF T HIS SECTION . 26 
 
 (b) The criteria for setting upp er payment limits shall include consideration of:  27 
 
  (1) The cost of administering the prescription drug product;  28 
 
  (2) The cost of delivering the prescription drug product to consumers;  [and] 29 
 
  (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL H AVE ON 30 
PROVIDERS OF 340B  DRUGS ; 31 
 SENATE BILL 357  9 
 
  
  (4) FOR AN UPPER PAYMENT LIMIT ON A DRUG THAT  IS DESIGNATED 1 
AS A DRUG FOR A RARE  DISEASE OR CONDITION , THE IMPACT OF THE UP PER 2 
PAYMENT LIMIT ON PAT IENTS WITH RARE DISE ASES ; AND  3 
 
  [(3)] (4) (5) Other relevant administrative cost s related to the prescription 4 
drug product.  5 
 
 [(c) The process for setting upper payment limits shall:  6 
 
  (1) Prohibit the application of an upper payment limit for a prescription 7 
drug product that is on the federal Food and Drug Administration prescriptio n drug 8 
shortage list; and  9 
 
  (2) Require the Board to:  10 
 
   (i) Monitor the availability of any prescription drug product for 11 
which it sets an upper payment limit; and  12 
 
   (ii) If there becomes a shortage of the prescription drug product in 13 
the State, reconsider or suspend the upper payment limit. ] 14 
 
 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIM IT FOR A 15 
DRUG THAT BECOMES A CURRENT SHORTAGE , THE BOARD MAY RECONSIDER THE 16 
PREVIOUSLY SET UPPER  PAYMENT LIMIT . 17 
 
  (2) THE BOARD MAY NOT : 18 
 
   (I) ESTABLISH  APPLY  A NEW UPPER PAYMENT LIMIT FOR  TO A 19 
DRUG IN  A CURRENT SHORTAGE ;  20 
 
   (II) ENFORCE AN UPPER PAYM ENT LIMIT AGAINST PR OVIDER 21 
OR PHARMACY REIMBURS EMENT REQUIREMENTS F OR MEDICARE PART C OR PART 22 
D PLANS ; OR 23 
 
   (III) COUNT A PHARMACY DISP ENSING FE E TOWARD OR 24 
SUBJECT A PHARMACY D ISPENSING FEE TO AN UPPER PAYMENT LIMIT . 25 
 
 (d) (1) If a plan of action is drafted under subsection (a) of this section, the 26 
Board shall submit the plan of action to the Legislative Policy Committee of the General 27 
Assembly, i n accordance with § 2 –1257 of the State Government Article, for its approval.  28 
 
  (2) The Legislative Policy Committee shall have 45 days to approve the 29 
plan of action.  30 
 
10 SENATE BILL 357   
 
   (3) If the Legislative Policy Committee does not approve the plan of action, 1 
the Boar d shall submit the plan to the Governor and the Attorney General for approval.  2 
 
  (4) The Governor and the Attorney General shall have 45 days to approve 3 
the plan of action.  4 
 
  (5) The Board may not set upper payment limits unless the plan is 5 
approved, in accordance with this subsection, by:  6 
 
   (i) The Legislative Policy Committee; or  7 
 
   (ii) 1. The Governor; and  8 
 
    2. The Attorney General.  9 
 
21–2C–14. 10 
 
 [(a) If a plan of action is approved under § 21 –2C–13(d) of this subtitle ] IN 11 
ACCORDANCE WITH THE PLAN OF ACTION APPRO VED BY THE LEGISLATIVE POLICY 12 
COMMITTEE ON OCTOBER 22, 2024 , the Board may set upper payment limits THROUGH 13 
REGULATIONS  for prescription drug products that are:  14 
 
  (1) Purchased or paid for by a unit of State or local government or an 15 
organization on behalf of a unit of State or local government, including:  16 
 
   (i) State or county correctional facilities;  17 
 
   (ii) State hospitals; and  18 
 
   (iii) Health clinics at State institutions of higher education;  19 
 
  (2) Paid for through a health ben efit plan on behalf of a unit of State or 20 
local government, including a county, bicounty, or municipal employee health benefit plan; 21 
or 22 
 
  (3) Purchased for or paid for by the Maryland State Medical Assistance 23 
Program.  24 
 
 [(b) The upper payment limits set u nder subsection (a) of this section shall:  25 
 
  (1) Be for prescription drug products that have led or will lead to an 26 
affordability challenge; and  27 
 
  (2) Be set in accordance with the criteria established in regulations 28 
adopted by the Board.  29 
 
 SENATE BILL 357  11 
 
  (c) (1) The B oard shall:  1 
 
   (i) Monitor the availability of any prescription drug product for 2 
which it sets an upper payment limit; and  3 
 
   (ii) If there becomes a shortage of the prescription drug product in 4 
the State, reconsider whether the upper payment limit should be suspended or altered.  5 
 
  (2) An upper payment limit set under subsection (a) of this section may not 6 
be applied to a prescription drug product while the prescription drug product is on the 7 
federal Food and Drug Administration prescription drug sh ortage list. ] 8 
 
[21–2C–16. 9 
 
 On or before December 1, 2026, the Board, in consultation with the Stakeholder 10 
Council, shall report to the Senate Finance Committee and the House Health and 11 
Government Operations Committee, in accordance with § 2 –1257 of the St ate Government 12 
Article, on:  13 
 
  (1) The legality, obstacles, and benefits of setting upper payment limits on 14 
all purchases and payor reimbursements of prescription drug products in the State; and  15 
 
  (2) Recommendations regarding whether the General Assembly  should 16 
pass legislation to expand the authority of the Board to set upper payment limits to all 17 
purchases and payor reimbursements of prescription drug products in the State. ] 18 
 
21–2C–16. 19 
 
 (A) (1) THE BOARD , IN CONSULTATION WITH  THE STAKEHOLDER 20 
COUNCIL , SHALL DETERMINE WHET HER, IN ADDITION TO SETTI NG UPPER PAYMENT 21 
LIMITS IN ACCORDANCE  WITH § 21–2C–14 OF THIS SUBTITLE , IT IS IN THE BEST 22 
INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR S ETTING 23 
UPPER PAYMENT LIMITS  FOR ALL  PURCHASES AND PAYOR REIMBURSEMENTS OF 24 
PRESCRIPTION DRUG PR ODUCTS IN THE STATE THAT THE BOARD DETERMINES 25 
HAVE LED OR WILL LEA D TO AN AFFORDABILIT Y CHALLENGE . 26 
 
  (2) WHEN MAKING A DETERMI NATION UNDER PARAGRA PH (1) OF 27 
THIS SUBSECTION , THE BOARD SHALL CONSIDER , IF APPLICABLE : 28 
 
   (I) CONTRACT AND BUDGET D ATA PROVIDED TO THE BOARD 29 
THAT DEMONSTRATES SA VINGS TO THE STATE OR LOCAL GOVERN MENTS AS A 30 
RESULT OF UPPER PAYM ENT LIMITS SET IN AC CORDANCE WITH § 21–2C–14 OF THIS 31 
SUBTITLE ; 32 
 
12 SENATE BILL 357   
 
    (II) SUCCESS OF SETTING UP PER PAYMENT LIMITS I N OTHER 1 
STATES ; AND 2 
 
   (III) EXPECTED SAVINGS FROM  MEDICARE MAXIMUM FAIR 3 
PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES . 4 
 
 (B) (1) IF THE BOARD MAKES AN AFFIRM ATIVE DETERMINATION UNDER 5 
SUBSEC TION (A) OF THIS SECTION , THE BOARD , IN CONSULTATION WITH  THE 6 
STAKEHOLDER COUNCIL , SHALL ESTABLISH A PR OCESS FOR SETTING UP PER 7 
PAYMENT LIMITS FOR ALL  PURCHASES AND PAYOR REIMBURSEMENTS OF 8 
PRESCRIPTION DRUG PR ODUCTS IN THE STATE THAT THE BOARD DETERMINES 9 
HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE . 10 
 
  (2) THE PROCESS ESTABLISH ED UNDER PARAGRAPH (1) OF THIS 11 
SUBSECTION SHALL : 12 
 
   (I) TO THE EXTENT APPROPR IATE , USE THE PLAN OF ACTI ON 13 
APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE ; AND 14 
 
   (II) OTHERWISE COMPLY WITH THE REQU IREMENTS FOR 15 
SETTING UPPER PAYMEN T LIMITS ESTABLISHED  UNDER THIS SUBTITLE . 16 
 
  (3) BEFORE ESTABLISHING A N UPPER PAYMENT LIMI T THAT APPLIES 17 
TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM , THE BOARD SHALL CONFER 18 
WITH THE MARYLAND MEDICAL ASSIS TANCE PROGRAM TO APPROVE TH E 19 
APPLICATION OF THE U PPER PAYMENT LIMIT B Y ASSESSING WHETHER THE 20 
PROPOSED UPPER PAYME NT LIMIT WILL : 21 
 
   (I) CONFLICT WITH THE MEDICAID DRUG REBATES 22 
PROGRAM , THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC),  OR ANY 23 
OTHER FEDERAL REQUIREMENTS AS APPL ICABLE ; AND  24 
 
   (II) REQUIRE ADDITIONAL FU NDING TO BE ALLOCATE D TO THE 25 
MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET .  26 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read 27 
as follows:  28 
 
Article – Health – General  29 
 
21–2C–16. 30 
 
 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , IF THE 31 
BOARD ESTABLISHES A P ROCESS UNDER SUBSECT ION (B) OF THIS SECTION , THE 32 
 SENATE BILL 357  13 
 
 BOARD SHALL SET UPPER  PAYMENT LIMITS FOR ALL  PURCHASES AND PAYOR 1 
REIMBURSEMENTS OF PR ESCRIPTION DRUG PROD UCTS IN THE STATE IN 2 
ACCORDANCE WITH THE PROCESS .  3 
 
  (2) THIS SUBSECTION DOES NOT APPLY WITH RESPE CT TO : 4 
 
   (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND 5 
D PLANS ; 6 
 
   (II) PURCHASES UNDER THE F EDERAL 340B  DRUG PRICING 7 
PROGRAM ; AND  8 
 
   (III) PURCHASES AND PAYOR R EIMBURSEMENTS UNDER  BY 9 
FEDERAL AGENCIES OR  FEDERAL PROGRAMS THA T ARE THE STATE IS  PREEMPTED  10 
FROM REGULATING  BY FEDERAL LAW  INCLUDING : 11 
 
    1. THE DEPARTMENT OF DEFENSE ; 12 
 
    2. THE DEPARTMENT OF VETERANS AFFAIRS ; 13 
 
    3. THE PUBLIC HEALTH SERVICE ; 14 
 
    4. THE UNITED STATES COAST GUARD ; 15 
 
    5. TRICARE ; 16 
 
    6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN; 17 
AND  18 
 
    7. ANY OTHER EXCLUSIVE F EDERAL PROGRAM AS 19 
APPLICABLE .  20 
 
 SECTION 3. AND BE IT FURTHER ENACTED, That:  21 
 
 (a) Section 2 of this  Act is contingent on the Prescription Drug Affordability Board 22 
setting upper payment limits on two prescription drugs in accordance with § 21 –2C–14 of 23 
the Health – General Article, as enacted by Section 1 of this Act, and each upper payment 24 
limit being in  effect for 1 year.  25 
 
 (b) Within 5 days after the conditions described in subsection (a) of this section 26 
are met, the Prescription Drug Affordability Board shall notify the Department of 27 
Legislative Services.  28 
 
 (c) If notice is received by the Department o f Legislative Services in accordance 29 
with subsection (b) of this section on or before September 31  September 30 , 2030, Section 2 30 
14 SENATE BILL 357   
 
 of this Act shall take effect on the date the notice is received by the Department of 1 
Legislative Services.  2 
 
 (d) If notice is not received by the Department of Legislative Services on or before 3 
December 31  September 30 , 2030, Section 2 of this Act, with no further action required by 4 
the General Assembly, shall be null and void.  5 
 
 SECTION 4. AND BE IT FURTHER ENACTED,  That, subject to Section 3 of this 6 
Act, this Act shall take effect October 1, 2025.  7 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
                 President of the Senate.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  